Get the Stockscreener App
23.62
1.89%
-0.465
Overview
News
Price History
Option Chain
Financials
Why PFE Down?
Discussions
Forecast
Stock Split
Dividend History
Pfizer Inc stock is traded at $23.62, with a volume of 41.13M.
It is down -1.89% in the last 24 hours and down -5.99% over the past month.
Pfizer is one of the world's largest pharmaceutical firms, with annual sales of roughly $60 billion. While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing 40% of total sales. Within international sales, emerging markets are a major contributor.
See More
Previous Close:
$24.09
Open:
$24.09
24h Volume:
41.13M
Relative Volume:
0.98
Market Cap:
$134.32B
Revenue:
$63.83B
Net Income/Loss:
$10.77B
P/E Ratio:
12.57
EPS:
1.88
Net Cash Flow:
$12.44B
1W Performance:
-2.13%
1M Performance:
-5.99%
6M Performance:
-7.50%
1Y Performance:
-18.30%
1-Day Range:
$23.62
$24.15
1-Week Range:
$23.62
$24.80
52-Week Range:
$20.91
$30.43
Pfizer Inc Stock (PFE) Company Profile
Name
Pfizer Inc
Sector
Industry
Phone
(212) 733-2323
Address
66 HUDSON BOULEVARD EAST, NEW YORK, NY
Compare PFE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFE
Pfizer Inc
|
23.62 | 136.96B | 63.83B | 10.77B | 12.44B | 1.88 |
|
LLY
Lilly Eli Co
|
712.40 | 665.04B | 53.26B | 13.80B | -50.20M | 15.30 |
|
JNJ
Johnson Johnson
|
176.94 | 425.53B | 90.62B | 22.66B | 18.18B | 9.35 |
|
ABBV
Abbvie Inc
|
218.77 | 388.63B | 58.33B | 3.73B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
122.35 | 238.11B | 53.40B | 13.68B | 16.89B | 6.9231 |
|
MRK
Merck Co Inc
|
77.76 | 199.00B | 63.43B | 16.42B | 14.72B | 6.49 |
Pfizer Inc Stock (PFE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-22-25 | Initiated | Cantor Fitzgerald | Neutral |
| Dec-10-24 | Resumed | BofA Securities | Neutral |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-25-24 | Resumed | Citigroup | Neutral |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Aug-07-24 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Mar-22-24 | Downgrade | Argus | Buy → Hold |
| Feb-23-24 | Initiated | Guggenheim | Buy |
| Jan-04-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Oct-20-23 | Resumed | UBS | Neutral |
| Oct-16-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-17-23 | Reiterated | JP Morgan | Neutral |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| Jun-29-23 | Downgrade | Credit Suisse | Outperform → Neutral |
| May-11-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-07-23 | Upgrade | Daiwa Securities | Neutral → Outperform |
| Jan-26-23 | Downgrade | UBS | Buy → Neutral |
| Jan-17-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-13-22 | Upgrade | Goldman | Neutral → Buy |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| May-23-22 | Initiated | SVB Leerink | Mkt Perform |
| Apr-06-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jan-05-22 | Upgrade | BofA Securities | Neutral → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-20-21 | Reiterated | Cowen | Outperform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-13-21 | Upgrade | UBS | Neutral → Buy |
| Dec-09-21 | Initiated | Wells Fargo | Overweight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Jul-27-21 | Resumed | Truist | Buy |
| May-06-21 | Downgrade | Mizuho | Buy → Neutral |
| Apr-07-21 | Resumed | RBC Capital Mkts | Sector Perform |
| Feb-04-21 | Upgrade | DZ Bank | Hold → Buy |
| Dec-16-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Nov-19-20 | Resumed | Goldman | Neutral |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Oct-12-20 | Downgrade | Atlantic Equities | Overweight → Neutral |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Jun-16-20 | Initiated | SVB Leerink | Mkt Perform |
| Feb-27-20 | Initiated | Barclays | Equal Weight |
| Feb-27-20 | Upgrade | Standpoint Research | Hold → Buy |
| Feb-06-20 | Initiated | Mizuho | Buy |
| Jan-07-20 | Initiated | RBC Capital Mkts | Outperform |
| Oct-17-19 | Resumed | BofA/Merrill | Neutral |
| Jul-30-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Jul-30-19 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jun-04-19 | Resumed | Morgan Stanley | Overweight |
| Feb-20-19 | Resumed | Citigroup | Neutral |
| Jan-31-19 | Upgrade | Argus | Hold → Buy |
| Jan-31-19 | Upgrade | Credit Suisse | Neutral → Outperform |
| Jan-23-19 | Downgrade | UBS | Buy → Neutral |
| Dec-11-18 | Downgrade | JP Morgan | Overweight → Neutral |
| Nov-01-18 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
View All
Pfizer Inc Stock (PFE) Latest News
Pfizer, BioNTech Challenge GSK Patents Over Vaccine Tech - Law360
Can a multibillion-dollar deal put Pfizer in the obesity big leagues? - PharmaVoice
November 7th Options Now Available For Pfizer (PFE) - Nasdaq
Does This Acquisition Make Pfizer Stock a Great Buy? - Nasdaq
Geriatric Medicines Market Set for Dynamic Growth with Key - openPR.com
Pfizer to showcase cancer drug data at ESMO Congress 2025 By Investing.com - Investing.com Canada
Essex Financial Services Inc. Purchases 29,086 Shares of Pfizer Inc. $PFE - MarketBeat
Ruffer LLP Sells 792,785 Shares of Pfizer Inc. $PFE - MarketBeat
MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH Decreases Stock Position in Pfizer Inc. $PFE - MarketBeat
Pfizer to showcase cancer drug data at ESMO Congress 2025 - Investing.com
Pfizer Highlights Momentum in Redefining Standards of Care in Cancer at ESMO 2025 - Business Wire
Pfizer Inc. $PFE Shares Purchased by Penn Davis Mcfarland Inc. - MarketBeat
Pfizer Tries to Fatten Its Profits With Weight Loss Drugs - Investing.com
Xcel Wealth Management LLC Reduces Stock Position in Pfizer Inc. $PFE - MarketBeat
Santori & Peters Inc. Purchases 11,000 Shares of Pfizer Inc. $PFE - MarketBeat
TD Private Client Wealth LLC Grows Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Sheets Smith Wealth Management Sells 27,150 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Is Buying Weight Loss Biotech Metsera. Here's Why Viking Therapeutics Shareholders May Be Cheering. - Yahoo Finance
Pfizer Agrees to Take Over Metsera for $4.9 Billion - CHEManager
Pneumococcal Vaccine Market Opportunities and Strategies to 2034 - GlobeNewswire Inc.
Pfizer Inc: Is Wall Street Wrong to Give Up on This Comeback Story? - Yahoo Finance
Dividend Stock Portfolio for Retirement: Pfizer’s (PFE) Reliable Payouts - Yahoo Finance
Pfizer boosts push for obesity treatments with $4.9B deal for Metsera - LiveNOW from FOX
Pfizer: Jefferies raises target price - MarketScreener
Foster Victor Wealth Advisors LLC Has $16.48 Million Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Sold by Public Employees Retirement System of Ohio - MarketBeat
Should You Forget Pfizer and Buy These Unstoppable Stocks Instead? - AOL.com
78,922 Shares in Pfizer Inc. $PFE Bought by IMS Capital Management - MarketBeat
With 67% institutional ownership, Pfizer Inc. (NYSE:PFE) is a favorite amongst the big guns - Yahoo Finance
Jefferies Adjusts Price Target on Pfizer to $34 From $33, Maintains Buy Rating - MarketScreener
Arvinas stock downgraded by BofA as Pfizer partnership shifts - Investing.com
Wilsey Asset Management Inc. Has $23.88 Million Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Sold by Fifth Third Bancorp - MarketBeat
Pfizer to buy obesity drug maker Metsera - Medical Dialogues
17,033 Shares in Pfizer Inc. $PFE Acquired by Revisor Wealth Management LLC - MarketBeat
Autozone, Pfizer, Valley National Bancorp - TradingView
Where Will Pfizer Be in 5 Years? - Nasdaq
PFIZER INC : Receives a Buy rating from Jefferies - MarketScreener
Pfizer bets on weight-loss drugs - Global Cosmetics News
Pfizer Invites Public to View and Listen to Webcast of November 4 Conference Call with Analysts - BioSpace
Pfizer Challenges Novo Nordisk and Eli Lilly with $7.3B Metsera Buyout - NAI500
How Pfizer Inc. (PFE) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Pfizer Raises EPS Guidance and Expands Cost-Cutting Plan While Boosting Dividend Appeal - Yahoo Finance
Pfizer Inc. (PFE) Targets $4.5B in Cost Savings to Fuel R&D and Innovative Therapies - Yahoo Finance
Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock? - Yahoo Finance
Pfizer’s Acquisition Of Metsera Bucks The Recent Trend For Obesity Deals - insights.citeline.com
Wachtell, Paul Weiss guide Pfizer’s $7.3bn buy of weight loss drugmaker Metsera - The Global Legal Post
Pfizer’s $5B Bet on Metsera ($MTSR) vs Viking Therapeutics ($VKTX) - MSN
Metsera (MTSR) Soars to All-Time High on $7.3-Billion Merger With Pfizer - MSN
Pfizer's $7.3B Gamble: Chasing Ozempic Rivals After Own Weight-Loss Pill Flopped - Yahoo Finance
Pfizer (PFE): Is This Healthcare Giant’s Valuation Now Too Low to Ignore? - simplywall.st
Pfizer Inc Stock (PFE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.97%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):